Skip to main content

Industry-sponsored studies

In recent years, centers of the German ALS/MND Network have participated in numerous international industry-sponsored studies and contributed to a significant proportion of recruited patients. Currently, centers of the German ALS-MND Network are involved in conducting the following industry studies:

Currently recruiting studies:

  • 233AS303; Sponsor: Biogen; ATLAS; A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation; NCT04856982.
    Hannover, Ulm
  • AP101-02; Sponsor: AL-S Pharma; A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmaco-kinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS); NCT05039099
    Berlin, Hannover, Ulm
  • ION363-CS1; Sponsor: IONIS: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS); NCT04768972
    Ulm
  • CORT113176-652; Sponsor: Corcept Therapeutics; DAZALS; Dazucorilant in Patients With Amyotrophic Lateral Sclerosis; NCT05407324
    Berlin, Bonn, Dresden, Hannover, Jena, Rostock, TU München, Ulm
  • PTC857-CNS-001-ALS; Sponsor: PTC Therapeutics, Inc.; CARDINALS; Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS; NCT05349721
    Berlin, Hannover, Lübeck, Rostock, Ulm
  • QRL-201-01; Sponsor: QurAlis Corporation; A Study Evaluating the Safety and Tolerability of QRL-201 in ALS; NCT05633459
    Berlin, Bonn, Lübeck, Ulm

Upcoming Studies:

  • AB 19001; Sponsor: AB Science; Masitinib: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients; NCT03127267
blank

Recruitment recently completed or stopped:

  • ACT16970; Sponsor: Sanofi; HIMALAYA: Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS); NCT05237284
    Berlin, Dresden, Hannover, Lübeck, Ulm
  • APL2-ALS-206; Sponsor: Apellis Pharmaceuticals, Inc.; MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS); NCT04579666
    Berlin, Hannover, Jena, Rostock, Ulm
  • ALXN1210-ALS-308; Sponsor: Alexion Pharmaceuticals, Inc.; Ravulizumab (ALXN1210): An Efficacy and Safety Study of Ravulizumab in ALS Participants; NCT04248465;
    Göttingen, Hannover, Jena, TU München, Ulm
  • MT-1186-A02: Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Edaravone (MT-1186): Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS; NCT04569084
    Berlin, Bochum, Bonn, Göttingen, Hannover, Jena, TU München, Rostock, Ulm, Wiesbaden, Würzburg
  • FAB 122-CT-2001; Sponsor: Ferrer Internacional, S.A.; ADORE: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis (ADORE); NCT05178810; Current Open Label Extension Phase
    Berlin, Dresden, Hannover, Ulm
  • A35-004; Sponsor: Amylyx Pharmaceuticals Inc.; AMX0035: A Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment; NCT05021536; Current Open Label Extension Phase
    Berlin, Dresden, Hannover, Jena, Mannheim, Rostock, Ulm
  • TPN-101-C9-201; Sponsor: Transposon Therapeutics, Inc: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD; NCT04993755. Study for patients with ALS or FTD with a C9orf72 mutation. Current Open Label Extension Phase; NCT04993755
    Ulm
  • 233AS102; Sponsor: Biogen; Long-Term Evaluation of BIIB067 (Tofersen); NCT03070119
    Ulm
  • CY 5031; Sponsor: Cytokinetics, Inc.; COURAGE-ALS: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS); NCT04944784
    Berlin, Bonn, Hannover, Jena, Lübeck, Ulm

Are you interested in collaborations, clinical studies, or scientific discussions with us?

Contact Us